668 related articles for article (PubMed ID: 19794442)
1. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
2. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
[TBL] [Abstract][Full Text] [Related]
3. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
Dickey CA; Petrucelli L
Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
[TBL] [Abstract][Full Text] [Related]
6. AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery.
Baker JD; Uhrich RL; Strovas TJ; Saxton AD; Kraemer BC
SLAS Discov; 2021 Mar; 26(3):400-409. PubMed ID: 32981422
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
8. Dementia Therapy Targeting Tau.
Buee L
Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
Wolfe MS
IDrugs; 2010 Dec; 13(12):828-9. PubMed ID: 21154135
[TBL] [Abstract][Full Text] [Related]
10. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
[TBL] [Abstract][Full Text] [Related]
11. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
12. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
13. Recent developments with tau-based drug discovery.
Iqbal K; Liu F; Gong CX
Expert Opin Drug Discov; 2018 May; 13(5):399-410. PubMed ID: 29493301
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
Moore KBE; Hung TJ; Fortin JS
Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
[TBL] [Abstract][Full Text] [Related]
15. Tau protein aggregation: Key features to improve drug discovery screening.
Giovannini J; Smeralda W; Jouanne M; Sopkova-de Oliveira Santos J; Catto M; Voisin-Chiret AS
Drug Discov Today; 2022 May; 27(5):1284-1297. PubMed ID: 35085785
[TBL] [Abstract][Full Text] [Related]
16. Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics.
Das G; Ghosh S
ACS Chem Neurosci; 2019 Mar; 10(3):1118-1120. PubMed ID: 30657675
[TBL] [Abstract][Full Text] [Related]
17. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.
Carlomagno Y; Chung DC; Yue M; Castanedes-Casey M; Madden BJ; Dunmore J; Tong J; DeTure M; Dickson DW; Petrucelli L; Cook C
J Biol Chem; 2017 Sep; 292(37):15277-15286. PubMed ID: 28760828
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic landscape of tauopathies: challenges and prospects.
Cummings JL; Gonzalez MI; Pritchard MC; May PC; Toledo-Sherman LM; Harris GA
Alzheimers Res Ther; 2023 Oct; 15(1):168. PubMed ID: 37803386
[TBL] [Abstract][Full Text] [Related]
19. Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer's Disease and Other Tauopathies.
Altendorf T; Gering I; Santiago-Schübel B; Aghabashlou Saisan S; Tamgüney G; Tusche M; Honold D; Schemmert S; Hoyer W; Mohrlüder J; Willbold D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768484
[TBL] [Abstract][Full Text] [Related]
20. Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.
Robert A; Schöll M; Vogels T
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
